Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.67 |
| ▸ | THRB | P10828 | 4/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.64 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4477254 | 0.95 | TGFBR1 (0.65) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL8326198 | 0.88 | TGFBR1 (0.74) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL8324394 | 0.85 | TGFBR1 (0.88) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL4479321 | 0.84 | TGFBR1 (0.85) | TGFBR1THRBMAPK14 | |
| Trifluoroacetic Acid SCHEMBL4491884 | 0.84 | TGFBR1 (0.76) | TGFBR1TGFBR2 | |
| SCHEMBL373074 | 0.82 | TGFBR1 (0.84) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL4471671 | 0.82 | TGFBR1 (0.80) | TGFBR1THRBMAPK14 | |
| SCHEMBL5235558 | 0.82 | TGFBR1 (0.87) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL4489877 | 0.82 | TGFBR1 (0.78) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL412973 | 0.82 | TGFBR1 (0.77) | TGFBR1THRBMAPK14TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| WO-2004048383-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | MYLK2, CSNK1G2, CSNK1A1 | TGFBR1 691/4885THRB 528/4885MAPK14 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.